MBA Advisors LLC Sells 67 Shares of Johnson & Johnson (NYSE:JNJ)

MBA Advisors LLC reduced its stake in shares of Johnson & Johnson (NYSE:JNJ) by 1.2% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 5,485 shares of the company’s stock after selling 67 shares during the period. MBA Advisors LLC’s holdings in Johnson & Johnson were worth $793,000 at the end of the most recent reporting period.

A number of other hedge funds also recently modified their holdings of JNJ. AMF Tjanstepension AB boosted its holdings in Johnson & Johnson by 14.2% in the 3rd quarter. AMF Tjanstepension AB now owns 425,261 shares of the company’s stock worth $68,985,000 after buying an additional 52,997 shares during the period. Alpha Financial Partners LLC purchased a new stake in shares of Johnson & Johnson during the third quarter worth $209,000. Wealth Group Ltd. bought a new position in shares of Johnson & Johnson in the third quarter worth $213,000. Wedge Capital Management L L P NC raised its stake in shares of Johnson & Johnson by 2.2% during the 3rd quarter. Wedge Capital Management L L P NC now owns 4,039 shares of the company’s stock valued at $655,000 after purchasing an additional 86 shares during the period. Finally, Creative Planning lifted its holdings in Johnson & Johnson by 4.3% during the 3rd quarter. Creative Planning now owns 988,403 shares of the company’s stock worth $160,181,000 after purchasing an additional 41,082 shares in the last quarter. Institutional investors own 69.55% of the company’s stock.

Insider Activity at Johnson & Johnson

In other news, Director Mark A. Weinberger acquired 1,000 shares of the firm’s stock in a transaction on Thursday, December 12th. The shares were purchased at an average price of $147.22 per share, for a total transaction of $147,220.00. Following the completion of the transaction, the director now owns 1,000 shares of the company’s stock, valued at $147,220. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 0.16% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on JNJ shares. Royal Bank of Canada reiterated an “outperform” rating and set a $181.00 price target on shares of Johnson & Johnson in a research report on Thursday, January 23rd. Leerink Partners lowered their target price on shares of Johnson & Johnson from $182.00 to $169.00 and set an “outperform” rating on the stock in a research note on Thursday, January 23rd. Argus upgraded shares of Johnson & Johnson to a “strong-buy” rating in a research report on Friday, January 24th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $215.00 price objective on shares of Johnson & Johnson in a research report on Wednesday, October 16th. Finally, Barclays boosted their target price on Johnson & Johnson from $159.00 to $166.00 and gave the stock an “equal weight” rating in a research report on Tuesday, January 28th. Nine analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $170.67.

Johnson & Johnson Price Performance

Shares of NYSE:JNJ opened at $155.23 on Thursday. The company has a quick ratio of 0.79, a current ratio of 1.03 and a debt-to-equity ratio of 0.45. The stock has a market cap of $373.73 billion, a PE ratio of 23.34, a PEG ratio of 2.46 and a beta of 0.52. The company’s fifty day moving average is $147.48 and its 200 day moving average is $156.01. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $168.85.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, beating analysts’ consensus estimates of $1.99 by $0.05. The company had revenue of $22.52 billion during the quarter, compared to analyst estimates of $22.44 billion. Johnson & Johnson had a return on equity of 34.35% and a net margin of 18.20%. Johnson & Johnson’s revenue for the quarter was up 5.3% on a year-over-year basis. During the same quarter in the previous year, the company posted $2.29 EPS. Research analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th will be paid a $1.24 dividend. This represents a $4.96 annualized dividend and a dividend yield of 3.20%. The ex-dividend date is Tuesday, February 18th. Johnson & Johnson’s payout ratio is 74.59%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.